NICK STULL: Open Payments
NPI 1053935890 · AMES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$254 in 13 payments from 8 companies in 2025. Trend: 2023 $781 · 2024 $340 · 2025 $254
Food & beverage: $254
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $86 |
| Lundbeck LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Tris Pharma Inc | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Corium, LLC | 1 | $7 |
Products named: FANAPT, REXULTI, TRINTELLIX, Dyanavel XR, VRAYLAR, CAPLYTA, Azstarys.
Industry payments across IA — which companies pay providers there.
